These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37691397)

  • 1. Current and preclinical treatment options for Merkel cell carcinoma.
    Celikdemir B; Houben R; Kervarrec T; Samimi M; Schrama D
    Expert Opin Biol Ther; 2023; 23(10):1015-1034. PubMed ID: 37691397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-Cell Responses in Merkel Cell Carcinoma: Implications for Improved Immune Checkpoint Blockade and Other Therapeutic Options.
    Gehrcken L; Sauerer T; Schaft N; Dörrie J
    Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445385
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for Merkel Cell Carcinoma.
    Nagase K; Narisawa Y
    Curr Treat Options Oncol; 2018 Sep; 19(11):57. PubMed ID: 30238195
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical and molecular characteristics associated with response to therapeutic PD-1/PD-L1 inhibition in advanced Merkel cell carcinoma.
    Spassova I; Ugurel S; Kubat L; Zimmer L; Terheyden P; Mohr A; Björn Andtback H; Villabona L; Leiter U; Eigentler T; Loquai C; Hassel JC; Gambichler T; Haferkamp S; Mohr P; Pfoehler C; Heinzerling L; Gutzmer R; Utikal JS; Horny K; Schildhaus HU; Habermann D; Hoffmann D; Schadendorf D; Becker JC
    J Immunother Cancer; 2022 Jan; 10(1):. PubMed ID: 35074902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Scientific and clinical developments in Merkel cell carcinoma: A polyomavirus-driven, often-lethal skin cancer.
    Akaike T; Nghiem P
    J Dermatol Sci; 2022 Jan; 105(1):2-10. PubMed ID: 34836718
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Merkel Cell Carcinoma.
    Strong J; Hallaert P; Brownell I
    Hematol Oncol Clin North Am; 2024 Oct; 38(5):1133-1147. PubMed ID: 39060119
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PD-L1 inhibition with avelumab for metastatic Merkel cell carcinoma.
    Gaiser MR; Bongiorno M; Brownell I
    Expert Rev Clin Pharmacol; 2018 Apr; 11(4):345-359. PubMed ID: 29478343
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Immune checkpoint inhibition in Merkel cell carcinoma].
    Terheyden P; Mohr A; Langan EA
    Hautarzt; 2019 Sep; 70(9):684-690. PubMed ID: 31468071
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pembrolizumab and other immune checkpoint inhibitors in locally advanced or metastatic Merkel Cell Carcinoma: safety and efficacy.
    Marchand A; Kervarrec T; Bhatia S; Samimi M
    Expert Rev Anticancer Ther; 2020 Dec; 20(12):1093-1106. PubMed ID: 33044876
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Modern diagnostics and treatment of Merkel cell carcinoma.
    Weilandt J; Peitsch WK
    J Dtsch Dermatol Ges; 2023 Dec; 21(12):1524-1546. PubMed ID: 37875785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Recent Therapeutic Advances and Change in Treatment Paradigm of Patients with Merkel Cell Carcinoma.
    Garcia-Carbonero R; Marquez-Rodas I; de la Cruz-Merino L; Martinez-Trufero J; Cabrera MA; Piulats JM; Capdevila J; Grande E; Martin-Algarra S; Berrocal A
    Oncologist; 2019 Oct; 24(10):1375-1383. PubMed ID: 30962295
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multimodal Strategy in Localized Merkel Cell Carcinoma: Where Are We and Where Are We Heading?
    Ricco G; Andrini E; Siepe G; Mosconi C; Ambrosini V; Ricci C; Casadei R; Campana D; Lamberti G
    Int J Mol Sci; 2021 Sep; 22(19):. PubMed ID: 34638968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Merkel Cell Carcinoma Therapeutic Update.
    Cassler NM; Merrill D; Bichakjian CK; Brownell I
    Curr Treat Options Oncol; 2016 Jul; 17(7):36. PubMed ID: 27262710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Avelumab: a new standard for treating metastatic Merkel cell carcinoma.
    Baker M; Cordes L; Brownell I
    Expert Rev Anticancer Ther; 2018 Apr; 18(4):319-326. PubMed ID: 29482384
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunotherapy for Merkel cell carcinoma: a turning point in patient care.
    Chan IS; Bhatia S; Kaufman HL; Lipson EJ
    J Immunother Cancer; 2018 Mar; 6(1):23. PubMed ID: 29566749
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Merkel Cell Carcinoma: Integrating Epidemiology, Immunology, and Therapeutic Updates.
    Becker JC; Stang A; Schrama D; Ugurel S
    Am J Clin Dermatol; 2024 Jul; 25(4):541-557. PubMed ID: 38649621
    [TBL] [Abstract][Full Text] [Related]  

  • 18. An update on Merkel cell carcinoma.
    Sergi MC; Lauricella E; Porta C; Tucci M; Cives M
    Biochim Biophys Acta Rev Cancer; 2023 May; 1878(3):188880. PubMed ID: 36914034
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Retrospective Study of Ipilimumab Plus Nivolumab in Anti-PD-L1/PD-1 Refractory Merkel Cell Carcinoma.
    Shalhout SZ; Emerick KS; Kaufman HL; Silk AW; Thakuria M; Miller DM
    J Immunother; 2022 Sep; 45(7):299-302. PubMed ID: 35877101
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current concepts and approaches to merkel cell carcinoma.
    Babadzhanov M; Doudican N; Wilken R; Stevenson M; Pavlick A; Carucci J
    Arch Dermatol Res; 2021 Apr; 313(3):129-138. PubMed ID: 32666149
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.